Singapore-based medical testing firm Mirxes joins Jiangsu Hengrui Pharmaceuticals in revitalised market’s listing surge.

Now, with tensions easing and the US$43.6 billion ($56.62 billion) raised in 2025 IPOs so far running just behind the same ...

SINGAPORE] Singapore biotech start-up Mirxes launched its initial public offering (IPO) in Hong Kong on Thursday (May 15) as ...

Hong Kong is calling for robotaxi operator Pony AI . The $6 billion Chinese company is exploring an offering in the city just ...

Alibaba reported a 93% YoY increase in operating income for the March 2025 quarter, driven by strong cloud revenue and sustained triple-digit growth in AI products. Total revenue rose 7% to RMB 236.5 ...

SINGAPORE] Local stocks climbed on Thursday (May 15), as investors assessed financial results from listed companies here.

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

City’s largest share sale in four years shows Beijing’s determination to push China’s EV technologies worldwide, analysts say ...

Bursa Malaysia's Securities Trading unit is facing headwinds because of weak equity sentiment brought about by the ongoing ...

The underwriters on Hengrui Pharmaceutical Hong Kong listing are represented by Herbert Smith Freehills and Jingtian & ...

Jiangsu Hengrui Pharmaceuticals is planning to raise as much as US$1.27 billion via an initial public offering in Hong Kong, joining a wave of Chinese companies seeking to tap the city's market.